Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 20 | 2024 | 2903 | 2.720 |
Why?
|
| Methotrexate | 11 | 2024 | 1033 | 2.050 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2024 | 1351 | 1.200 |
Why?
|
| Leukemia | 3 | 2024 | 1721 | 1.020 |
Why?
|
| Allopurinol | 4 | 2023 | 86 | 1.010 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2020 | 205 | 0.930 |
Why?
|
| Lymphoma | 4 | 2024 | 1513 | 0.860 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 135 | 0.720 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 126 | 0.700 |
Why?
|
| Eosinophilia | 1 | 2020 | 188 | 0.620 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2017 | 10 | 0.600 |
Why?
|
| Ketones | 1 | 2018 | 59 | 0.600 |
Why?
|
| Furans | 1 | 2018 | 103 | 0.600 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 331 | 0.600 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 316 | 0.580 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 629 | 0.570 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 86 | 0.550 |
Why?
|
| Child | 24 | 2024 | 30576 | 0.520 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 429 | 0.510 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1289 | 0.480 |
Why?
|
| Histiocytosis, Sinus | 1 | 2015 | 87 | 0.480 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 533 | 0.460 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 3856 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 10369 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 16630 | 0.440 |
Why?
|
| Child, Preschool | 13 | 2024 | 17070 | 0.430 |
Why?
|
| Infant | 11 | 2024 | 13995 | 0.430 |
Why?
|
| Vincristine | 1 | 2017 | 1584 | 0.420 |
Why?
|
| Sirolimus | 2 | 2022 | 839 | 0.410 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 438 | 0.390 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2123 | 0.380 |
Why?
|
| Mercaptopurine | 4 | 2022 | 131 | 0.360 |
Why?
|
| Algorithms | 2 | 2018 | 3926 | 0.350 |
Why?
|
| Adolescent | 15 | 2024 | 32743 | 0.340 |
Why?
|
| Nucleosides | 1 | 2009 | 63 | 0.340 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1443 | 0.320 |
Why?
|
| Genotype | 1 | 2017 | 4276 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5418 | 0.310 |
Why?
|
| CpG Islands | 1 | 2010 | 662 | 0.290 |
Why?
|
| Tissue Distribution | 2 | 2019 | 946 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2672 | 0.280 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 369 | 0.270 |
Why?
|
| Humans | 34 | 2024 | 271967 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 7259 | 0.250 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 1323 | 0.250 |
Why?
|
| Laxatives | 1 | 2024 | 17 | 0.240 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2024 | 218 | 0.230 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 224 | 0.230 |
Why?
|
| Constipation | 1 | 2024 | 184 | 0.220 |
Why?
|
| Azacitidine | 1 | 2010 | 1219 | 0.220 |
Why?
|
| Thioguanine | 2 | 2022 | 70 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3264 | 0.210 |
Why?
|
| Male | 17 | 2024 | 129048 | 0.210 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 1966 | 0.210 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 49 | 0.200 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 817 | 0.200 |
Why?
|
| Spinal Cord Diseases | 1 | 2022 | 89 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 5103 | 0.200 |
Why?
|
| Neoplasms | 2 | 2018 | 15913 | 0.190 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 202 | 0.180 |
Why?
|
| Down Syndrome | 1 | 2023 | 227 | 0.180 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 59 | 0.170 |
Why?
|
| DNA Methylation | 1 | 2010 | 2762 | 0.170 |
Why?
|
| Female | 16 | 2024 | 149251 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 550 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 770 | 0.160 |
Why?
|
| Cytarabine | 2 | 2022 | 2014 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 15264 | 0.160 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 1741 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 263 | 0.150 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 48 | 0.140 |
Why?
|
| Prognosis | 5 | 2024 | 22542 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14647 | 0.140 |
Why?
|
| Vidarabine | 1 | 2022 | 1383 | 0.140 |
Why?
|
| Hypoglycemia | 1 | 2018 | 220 | 0.140 |
Why?
|
| Patient Selection | 1 | 2024 | 2038 | 0.140 |
Why?
|
| Microtubules | 1 | 2018 | 330 | 0.140 |
Why?
|
| Antiemetics | 1 | 2017 | 123 | 0.140 |
Why?
|
| Young Adult | 5 | 2024 | 22167 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 6988 | 0.130 |
Why?
|
| Morpholines | 1 | 2017 | 296 | 0.130 |
Why?
|
| Vomiting | 1 | 2017 | 361 | 0.130 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 174 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 214 | 0.120 |
Why?
|
| Unrelated Donors | 1 | 2016 | 321 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 39817 | 0.100 |
Why?
|
| Bortezomib | 2 | 2024 | 542 | 0.090 |
Why?
|
| Risk Factors | 2 | 2018 | 18028 | 0.090 |
Why?
|
| Mucositis | 2 | 2024 | 150 | 0.090 |
Why?
|
| Leukemia, T-Cell | 1 | 2009 | 90 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 176 | 0.080 |
Why?
|
| Splenic Neoplasms | 1 | 2009 | 125 | 0.080 |
Why?
|
| Adult | 4 | 2024 | 81964 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 834 | 0.070 |
Why?
|
| United States | 1 | 2024 | 16018 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 462 | 0.070 |
Why?
|
| Survival Rate | 1 | 2019 | 12545 | 0.070 |
Why?
|
| Neutropenia | 2 | 2024 | 1001 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8631 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2018 | 13398 | 0.060 |
Why?
|
| Remission Induction | 1 | 2009 | 3645 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 240 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2348 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 10260 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 543 | 0.050 |
Why?
|
| Etoposide | 1 | 2022 | 905 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2022 | 470 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 3946 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 251 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2011 | 33911 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 356 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 9476 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2022 | 1229 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 1719 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 1575 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 196 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 729 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 3243 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2017 | 355 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14882 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 25 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 45 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 20 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 98 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 67 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1438 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 684 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 79 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 432 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 153 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 4819 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 522 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3538 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 782 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 4887 | 0.020 |
Why?
|